SCHEMBL4771960

SCHEMBL4771960

Nc1ccc(-n2c3c(c4ccccc42)C(=O)CCC3)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.43
NFKB1 P19838 1/20 0.43
PMP22 Q01453 1/20 0.43
OPRM1 P35372 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
ALDH1A1 P00352 3/20 0.40
POLB P06746 1/20 0.40
HTR6 P50406 2/20 0.39
PTGS1 P23219 2/20 0.37
PTGS2 P35354 2/20 0.37
CREBBP Q92793 2/20 0.36
TP53 P04637 1/20 0.36
CNR1 P21554 2/20 0.36
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 1/20 0.36
GRM4 Q14833 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CSNK2B P67870 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147078 0.85 HDAC1 (0.48) OPRM1HDAC1HDAC6PTGS1PTGS2
SCHEMBL5145540 0.82 GRM4 (0.43) OPRM1HDAC1HDAC6PTGS1PTGS2
SCHEMBL4762936 0.81 ALDH1A1 (0.45) OPRM1HDAC1HDAC6ALDH1A1POLB
SCHEMBL5147135 0.81 HDAC1 (0.43) NFKB1OPRM1HDAC1HDAC6ALDH1A1
SCHEMBL5147134 0.79 LMNA (0.45) OPRM1HDAC1HDAC6ALDH1A1PTGS1
SCHEMBL5147107 0.77 CYP2D6 (0.48) CYP3A4HDAC1HDAC6ALDH1A1POLB
SCHEMBL5148161 0.76 TP53 (0.41) OPRM1HDAC1HDAC6ALDH1A1PTGS1
SCHEMBL5147168 0.75 PTGS1 (0.51) OPRM1HDAC1HDAC6ALDH1A1PTGS1
SCHEMBL5145428 0.75 DOT1L (0.45) HDAC1HDAC6PTGS1PTGS2CREBBP
SCHEMBL4791814 0.74 PTGS1 (0.45) OPRM1HDAC1HDAC6PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1924557-A2 CARBAZOLE DERIVATIVES Serenex, Inc. (US) 2008-05-28 EP claimed
US-20070185184-A1 Carbazole derivatives SERENEX, INC. 2007-08-09 US claimed
WO-2007035620-A2 CARBAZOLE DERIVATIVES SERENEX, INC. (US) 2007-03-29 WO claimed
EP-1924557-A2 CARBAZOLE DERIVATIVES Serenex, Inc. (US) 2008-05-28 EP disclosed
US-20070185184-A1 Carbazole derivatives SERENEX, INC. 2007-08-09 US disclosed
US-20070185184-A1 Carbazole derivatives SERENEX, INC. 2007-08-09 US disclosed
US-20070185184-A1 Carbazole derivatives SERENEX, INC. 2007-08-09 US disclosed
WO-2007035620-A2 CARBAZOLE DERIVATIVES SERENEX, INC. (US) 2007-03-29 WO disclosed
WO-2007035620-A2 CARBAZOLE DERIVATIVES SERENEX, INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185184-A1 Carbazole derivatives CCNI, MKI67, CCNB3 CYP3A4 654/4885NFKB1 416/4885PMP22 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.